Pediatrics – Rheumatology | Links Medicus Content Curation & Alerts in Medicine

RCT | Baricitinib demonstrates efficacy in treatment-resistant juvenile idiopathic arthritis

2 Aug, 2023 | 13:45h | UTC

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

NEW in @TheLancet—Baricitinib was efficacious with an acceptable safety profile in patients with #juvenile idiopathic #arthritis in a phase 3 withdrawal trialhttps://t.co/vZyXUwBiDZ #JIA

Plus linked Comment: https://t.co/VWofLvL427 pic.twitter.com/MGVoUz4xIv

— The Lancet Rheumatology (@TheLancetRheum) July 10, 2023

Consensus Paper | Methotrexate for inflammatory skin disease in pediatric patients

7 Jul, 2023 | 16:16h | UTC

Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines – Pediatrics Dermatology

Consensus Statement | Evaluation and management of deficiency of adenosine deaminase 2

30 Jun, 2023 | 14:53h | UTC

Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus Statement – JAMA Network Open

Invited Commentary: Finding a Quorum in Deficiency of Adenosine Deaminase 2 Management – JAMA Network Open

Podcast | Childhood-Onset SLE

6 Apr, 2023 | 13:12h | UTC

#77: Childhood-Onset SLE – Is It Sometimes Lupus? – The Cribsiders

RCT | Hydroxychloroquine in children with proliferative lupus nephritis

30 Mar, 2023 | 14:11h | UTC

Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial – European Journal of Pediatrics

RCT | Genicular nerve block vs. intra-articular triamcinolone in juvenile idiopathic arthritis

10 Feb, 2023 | 13:36h | UTC

Genicular nerve block in juvenile idiopathic arthritis: a randomized clinical trial – Clinical Rheumatology

RCT | Methylprednisolone vs. immunoglobulins equally effective in PIMS temporally associated with SARS-CoV-2

8 Feb, 2023 | 12:42h | UTC

Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial – The Lancet Child & Adolescent Health

SR | Intravenous immunoglobulin for the treatment of Kawasaki disease

7 Feb, 2023 | 13:58h | UTC

Intravenous immunoglobulin for the treatment of Kawasaki disease – Cochrane Library

Summary: Immunoglobulin treatment for Kawasaki disease – Cochrane Library

Analysis of Coronary Arterial Aneurysm Regression in Patients With Kawasaki Disease by Aneurysm Severity: Factors Associated With Regression – Journal of the American Heart Association

Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan – JAMA Network Open

Systematic Review: Corticosteroids for the treatment of Kawasaki disease in children.

Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives – Frontiers in Medicine

Cohort Study | Analysis of factors associated with coronary arterial aneurysm regression in patients with Kawasaki disease

7 Feb, 2023 | 13:56h | UTC

Analysis of Coronary Arterial Aneurysm Regression in Patients With Kawasaki Disease by Aneurysm Severity: Factors Associated With Regression – Journal of the American Heart Association

Intravenous immunoglobulin for the treatment of Kawasaki disease – Cochrane Library

Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan – JAMA Network Open

Systematic Review: Corticosteroids for the treatment of Kawasaki disease in children.

Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives – Frontiers in Medicine

2ry analysis of a RCT | Vitamin D supplementation did not influence growth, body composition, and pubertal development in children.

30 Nov, 2022 | 13:49h | UTC

Influence of Vitamin D Supplementation on Growth, Body Composition, and Pubertal Development Among School-aged Children in an Area With a High Prevalence of Vitamin D Deficiency: A Randomized Clinical Trial – JAMA Pediatrics (free for a limited period)

Commentary: Vitamin D Supplementation Does Not Influence Growth in Children – HealthDay

Recommendations for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis.

3 Nov, 2022 | 14:01h | UTC

Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-associated Uveitis – The Journal of Rheumatology

RCT | Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis.

15 Aug, 2022 | 12:05h | UTC

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial – Annals of Rheumatic Diseases

EULAR/PRES recommendations for vaccination of pediatric patients with autoimmune inflammatory rheumatic diseases.

24 Jun, 2022 | 11:17h | UTC

EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021 – Annals of Rheumatic Diseases

EULAR/ACR points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases.

24 Jun, 2022 | 11:23h | UTC

The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist – Annals of Rheumatic Diseases

Consensus Paper: Diagnosis and treat-to-target management of macrophage activation syndrome in children.

24 Jun, 2022 | 11:13h | UTC

Egyptian evidence-based consensus on clinical practice guidelines for the diagnosis and treat-to-target management of macrophage activation syndrome in children – Egyptian Rheumatology and Rehabilitation

Cohort Study: Association of maternal autoimmune diseases with risk of mental disorders in offspring in Denmark.

20 Apr, 2022 | 09:19h | UTC

Association of Maternal Autoimmune Diseases With Risk of Mental Disorders in Offspring in Denmark – JAMA Network Open

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1515057370715594753

RCT: Long-term efficacy and safety of up to 108 weeks of Ixekizumab in pediatric patients with moderate to severe plaque psoriasis.

18 Apr, 2022 | 09:49h | UTC

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial – JAMA Dermatology

Original Study: Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) – British Journal of Dermatology

Commentary on Twitter

In this RCT, by 108 weeks of use of ixekizumab for pediatric psoriasis, PASI 75/90/100 were achieved in 92%/79%/55%, respectively, of children, with clearance of nails in 68%, scalp in 76%, genital lesions in 88%, and palm/sole involvement in 90%. https://t.co/vk73Z3MKi4

— JAMA Dermatology (@JAMADerm) April 13, 2022